SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...
Edwards Lifesciences might be a pioneer in the transcatheter aortic valve replacement market, but that doesn’t mean it’s smooth sailing in the space. The Irvine, CA-based company faces stiff ...
SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback